TAZ, also known as WWTR1, has been identified to drive tumor formation, survival, stemness, progression, metastasis, and resistance to therapy; and TAZ overexpression has been associated with development, progression, and poor prognosis in NSCLC. Here, WWTR1 is linked to non-small cell lung carcinoma.